Metsra (MTSR) dropped 4.4% on a report that the Federal Trade Commission may have some concerns about Novo Nordisk’s (NVO) offer.
Staff members at the FTC said it appears Novo Nordisk (NVO) bid for Metsera (MTSR) “may violate the procedural provisions” of the law that requires a premerger review, according to a Bloomberg report on Wednesday, which cites a letter to lawyers for Pfizer (PFE) and Metsera that was sent by an FTC staff member.
Pfizer (PFE) and Novo Nordisk (NVO) are currently in a bidding war for Metsera (MTSR). Pfizer (PFE) on Friday sued Metsera (MTSR), alleging breach of contract, breach of fiduciary duty, and tortious interference in contract due to Metsera’s breach of its obligations after it agreed to merge with Pfizer. Pfizer on Monday said it filed a second lawsuit against Metsera, saying the Novo Nordisk (NVO) deal would violate antitrust laws.
